Gaddis, Nathan
Mathur, Ravi
Marks, Jesse
Zhou, Linran
Quach, Bryan
Waldrop, Alex
Levran, Orna
Agrawal, Arpana
Randesi, Matthew
Adelson, Miriam
Jeffries, Paul W.
Martin, Nicholas G.
Degenhardt, Louisa
Montgomery, Grant W.
Wetherill, Leah
Lai, Dongbing
Bucholz, Kathleen
Foroud, Tatiana
Porjesz, Bernice
Runarsdottir, Valgerdur
Tyrfingsson, Thorarinn
Einarsson, Gudmundur
Gudbjartsson, Daniel F.
Webb, Bradley Todd
Crist, Richard C.
Kranzler, Henry R.
Sherva, Richard
Zhou, Hang
Hulse, Gary
Wildenauer, Dieter
Kelty, Erin
Attia, John
Holliday, Elizabeth G.
McEvoy, Mark
Scott, Rodney J.
Schwab, Sibylle G.
Maher, Brion S.
Gruza, Richard
Kreek, Mary Jeanne
Nelson, Elliot C.
Thorgeirsson, Thorgeir
Stefansson, Kari
Berrettini, Wade H.
Gelernter, Joel
Edenberg, Howard J.
Bierut, Laura
Hancock, Dana B.
Johnson, Eric Otto
Funding for this research was provided by:
National Institute on Drug Abuse (R01DA044014, R01DA038632, R33DA027486, K01DA036751, R01DA04401)
Dr. Miriam and Sheldon G. Adelson Medical Research Foundation
National Institute on Alcohol Abuse and Alcoholism (U10AA008401)
European Commission to the painFACT project (H2020-2020-848099)
Pennsylvania State Department of Health Tobacco Settlement (non-formulary grant Pharmacogenetics of Opioid Use Disorder)
National Center for Advancing Translational Sciences (UL1RR024143)
Article History
Received: 27 July 2022
Accepted: 21 September 2022
First Online: 7 October 2022
Competing interests
: The authors declare no competing interests.